Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people start a weight loss injection thinking about the first few months. The longer picture matters just as much. Mounjaro and Wegovy are both licensed in the UK for ongoing use in adults who meet the clinical criteria, and the trial data behind them runs to 68–72 weeks — long enough to show what sustained use looks like in practice. These are prescription-only medicines; a GPhC-registered prescriber assesses whether long-term treatment is appropriate for you personally, reviewing your progress at every stage. This page brings together what the clinical evidence, NHS guidance, and current UK licensing actually say about continuing these medicines beyond the early months.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
It's a question our prescribers hear most weeks: how long should I actually stay on this? The honest answer is that there is no universal number. Both Mounjaro and Wegovy are licensed for sustained use alongside a reduced-calorie diet and increased physical activity; the licensed duration is open-ended, not capped at six or twelve months the way some people assume. The clinical trials that informed their approval ran to 68–72 weeks precisely because the regulators and manufacturers needed to understand what prolonged treatment looks like, not just an early burst of results.
What the evidence does show is that the medicines work while you take them. Appetite regulation, slower gastric emptying, and the hormonal signalling these drugs support do not build a permanent change in your physiology; they support it. That has real implications for what happens when treatment stops, which the next section covers honestly. If you are weighing up whether to continue, you can read about how long you can use weight loss injections alongside a conversation with your prescriber, not a forum thread.
NICE's appraisal of tirzepatide (TA1026) notes that if someone has not lost at least 5% of their body weight after six months at the highest tolerated dose, continuing treatment should be reviewed. That review is a clinical safeguard, not a failure point.
The regain evidence is one of the more important things to understand before you start, not after. In semaglutide extension studies, participants who stopped the injection after 68 weeks regained a substantial portion of their lost weight within the following twelve months, roughly two-thirds of what they had lost, on average. Tirzepatide data follows a similar pattern. This is not unique to GLP-1 medicines; it reflects the underlying biology of weight regulation, which these drugs support rather than permanently reset.
This does not mean you are locked in forever. It does mean the decision to stop is a clinical conversation, not something to do because you have hit a target number on the scales. Some people find it helpful to understand whether weight loss injections can be used short term before deciding on their approach; others continue longer-term; some pause and restart. Your prescriber at our pharmacy reviews your case before every repeat order, there are no automatic renewals, and no continuation without a fresh clinical assessment. That model keeps the medicine working in service of your health rather than the other way round.
For a fuller picture of what sustained use involves over time, the NHS's weight management injections guidance covers both the clinical rationale and the support that should sit alongside treatment.
The gastrointestinal side effects that catch most people off guard in the early weeks (nausea, loose stools, reflux, or fatigue) typically settle as your body adjusts to each dose level. That pattern tends to repeat with each titration step rather than worsening indefinitely. By the time most people reach a maintenance dose, the acute GI phase is largely behind them, though individual experience varies. A small number of people find GI symptoms persist; the right response is always a conversation with your prescriber rather than pushing through.
Less common but more serious effects require ongoing vigilance throughout treatment, not just at the start. Pancreatitis is an infrequent but recognised risk: the MHRA's Drug Safety Update for GLP-1 medicines (January 2026) specifically highlighted acute pancreatitis, with the key signal being severe stomach pain that reaches through to the back, with or without vomiting. That warrants urgent medical attention at any point in treatment. People often find it useful to understand what the long term effects of weight loss injections can look like alongside the more detailed information on the side effects over the long term page.
Injection technique also matters more than people expect. Rotating sites (abdomen, thigh, upper arm) and changing the needle with each dose keeps injections comfortable and effective. If you need a practical reminder on disposal, a sharps container is a simple and legally required step for used pens at home.
One thing that shapes long-term treatment more than people expect is the practical question of how to sustain it. The weight loss injections available in the UK are prescription-only medicines, and private monthly costs vary by dose and provider. A realistic plan accounts for that from the start rather than six months in. It is worth understanding what a quoted price actually includes before you commit: some providers charge separately for consultations, prescriptions, delivery, and any clinical follow-up after purchase.
At nume, one transparent price covers the consultation, the prescription, the medicine, and free next-working-day delivery. No subscription, no auto-renewal, and a prescriber reviews your case before every repeat. Current pricing is shown on the treatment page. We are not the cheapest option (that is a deliberate choice) because long-term treatment deserves ongoing clinical oversight, not a checkout process.
The NHS does prescribe both tirzepatide and semaglutide, but eligibility criteria are strict and rollout is phased; waiting lists for specialist services can be long. For people who do not yet meet NHS thresholds or who do not want to wait, a regulated private route remains the practical alternative. If you are thinking about where to begin, our treatment overview sets out what is licensed and what the assessment involves. When you are ready, check your eligibility with our prescribing team.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.